An overwhelming majority of West Virginia registered voters support a range of protections against fraud and scams that use ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

(RTTNews) - Axogen, Inc. (AXGN) announced that the U.S. Food and Drug Administration has approved the Biologics License Application (BLA) for AVANCE, an acellular nerve allograft (arwx). AXGN closed ...

Clinical trial findings showed Avance was noninferior to a collagen nerve cuff for returning sensory function in patients with nerve injuries in the hand. The Food and Drug Administration (FDA) has ...

Avance Biosciences opened its new Potency and Cell-Based Assay Center of Excellence, a purpose-built facility designed to expand and centralize the company’s capabilities in potency and functional ...

Dec 3 (Reuters) - The U.S. Food and Drug Administration has approved Axogen's (AXGN.O), opens new tab nerve repair graft, the health regulator said on Wednesday, paving the way for 12 years of ...

ADELAIDE, Australia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Avance Clinical, the Australia-based global CRO partner for biotechs, has been a leader in early phase clinical research for more than 30 years.

After leading the Apaches to a national championship in the spring, Micah Avance is officially the new head coach of the Tyler Junior College tennis programs. Doug Wren, athletic director, and Dr.

JavaScript’s low bar to entry has resulted in one of the richest programming language ecosystems in the world. This month’s report celebrates the bounty, while also highlighting a recent example of ...

Avance Clinical, a partner for biotechs providing global contract research organization services, has now guided 710 emerging biotechs through critical clinical trial inflection points. Avance ...

Shares of Axogen fell more than 15% in premarket trading Monday after the U.S. Food and Drug Administration extended by three months its review of the proposed transition of the company's Avance nerve ...

The U.S. Food and Drug Administration (FDA) on Monday extended the Prescription Drug User Fee Act (PDUFA) goal date for Axogen Inc.’s (NASDAQ:AXGN) Biologics License Application (BLA) for Avance Nerve ...